Preview

Артериальная гипертензия

Расширенный поиск

РАМИПРИЛ - универсальный органопротектор

https://doi.org/10.18705/1607-419X-2007-13-3-220-224

Полный текст:

Об авторе

В. Н. Хирманов
Всероссийский центр экстренной и радиационной медицины, Санкт-Петербург
Россия


Список литературы

1. Agabiti-Rosei E, Ambrosioni E, Dal Palù C, Muiesan ML, Zanchetti A. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J Hypertens. 1995. - 13(11). - 1325-1334.

2.

3. Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med. 2006. - 144(9). - 660-664.

4.

5. Berkenboom G, Fontaine D, Unger P, Baldassarre S, Preumont N, Fontaine J. Absence of nitrate tolerance after long-term treatment with ramipril: an endothelium-dependent mechanism. J Cardiovasc Pharmacol. 1999. - 34(4). - 547-553.

6.

7. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J; HOPE Investigators. Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002. - 324(7339). - 699-702.

8.

9. Cleland JG, Erhardt L, Murray G, Hall AS, Ball SG. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J. 1997. - 18(1). - 41-51.

10.

11. DREAM Trial Investigators, Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR.Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006. - 12;355(15). - 1551- 1562.

12.

13. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000. - 355(9200). - 253- 259.

14.

15. Ghiadoni L, Versari D, Magagna A, Kardasz I, Plantinga Y, Giannarelli C, Taddei S, Salvetti A. Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients. J Hypertens. 2007. - 25(2). - 361-366.

16.

17. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Lancet. - 2000. - 355(9200). - 253-259.

18.

19. Kaplan NM, Sproul LE, Mulcahy WS. Large prospective study of ramipril in patients with hypertension. CARE Investigators. Clin Ther. 1993. - 15(5). - 810-818.

20.

21. Kjøller-Hansen L, Steffensen R, Grande P. The Angiotensin- converting Enzyme Inhibition Post Revascularization Study (APRES). J Am Coll Cardiol. 2000. - 35(4). - 881-888.

22.

23. Lièvre M, Guйret P, Gayet C, Roudaut R, Haugh MC, Delair S, Boissel JP. Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. HYCAR Study Group. Hypertension. 1995. - 25(1). - 92-97.

24.

25. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, Moore- Cox A, Bosch J, Riley W, Teo K; SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001. - 103(7). - 919-925.

26.

27. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C; Task Force on ACE-inhibitors of the European Society of Cardiology. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J. 2004. - 25(16). - 1454-1470.

28.

29. Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Mйnard J; DIABHYCAR Study Investigators. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ. 2004. - 328(7438). - 495- 499.

30.

31. O'Hare P, Bilbous R, Mitchell T, O' Callaghan CJ, Viberti GC. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care. 2000. - 23(12). - 1823-1829.

32.

33. Ostergren J., Sleight P., Dagenais G., Danisa K., Bosch J., Qilong Y., Yusuf S. HOPE study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004. - 25(1). - 17-24.

34.

35. Otto A, Fontaine J, Berkenboom G. Ramipril treatment protects against nitrate-induced oxidative stress in eNOS-/- mice: An implication of the NADPH oxidase pathway. J. Cardiovasc Pharmacol. 2006. - 48(1). - 842-849.

36.

37. Pilote L, Abrahamowicz M, Rodrigues E, Eisenberg MJ, Rahme E. Mortality rates in elderly patients who take different angiotensin- converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med. 2004. - 141(2). - 102-12.

38.

39. Ruggenenti P, Perna A, Benini R, Bertani T, Zoccali C, Maggiore Q, Salvadori M, Remuzzi G. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time- dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol. 1999. - 10(5). - 997-1006.

40.

41. Salehian O, Healey J, Stambler B, Alnemer K, Almerri K, Grover J, Bata I, Mann J, Matthew J, Pogue J, Yusuf S, Dagenais G, Lonn E; HOPE Investigators.Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am Heart J. 2007. - 154(3). - 448-453.

42.

43. Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007. - 30(6). - 1351-1356.

44.

45. Stoll G., Bendszus M. Inflammation and Atherosclerosis. Novel Insights Into Plaque Formation and Destabilization. Stroke. - 2006. - 37 (7). - 1923-1932.

46.

47. Teo KK, Mitchell LB, Pogue J, Bosch J, Dagenais G, Yusuf S; HOPE Investigators. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. Circulation. 2004. - 110(11). - 1413-1417.

48.

49. Williams B, Gosse P, Lowe L, Harper R; PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens. 2006. - 24(1). :193-200.

50.

51. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study GroupEffect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. - 20;288(19). :2421-2431.

52.

53. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais GEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000. 342(3). 145-153.

54.

55. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B; HOPE Study Investigators. Ramipril and the development of diabetes. JAMA. 2001. - 286(15). - 882-1885.

56.


Для цитирования:


Хирманов В.Н. РАМИПРИЛ - универсальный органопротектор. Артериальная гипертензия. 2007;13(3):220-224. https://doi.org/10.18705/1607-419X-2007-13-3-220-224

For citation:


Khirmanov V.N. Ramipril as a universal oragnoprotector. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2007;13(3):220-224. (In Russ.) https://doi.org/10.18705/1607-419X-2007-13-3-220-224

Просмотров: 150


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)